Oxycodone extended release- Ensysce Biosciences

Drug Profile

Oxycodone extended release- Ensysce Biosciences

Alternative Names: BIO-MD™ PF614; ER Oxycodone - Ensysce Biosciences; ER Oxycodone Bio-MD™ System; PF 614; PRF 06014; PRF06104

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 03 Apr 2017 Ensysce Biosciences completes a phase I trial in Pain (In volunteers) in USA (PO)
  • 16 Dec 2016 Extended release oxycodone is available for licensing as of 16 Dec 2016. www.signaturerx.com
  • 01 Nov 2016 Phase-I clinical trials in Pain (In volunteers) in USA (PO) (NCT02454712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top